Company news

Immatics N.V. news in 2024

Immatics N.V.'s news releases, calls and decks from 2024, newest first.

View company

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

November 17, 2024

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

November 7, 2024

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

October 9, 2024

Immatics Announces Proposed $150 Million Public Offering

October 9, 2024

Immatics Announces Pricing of $150 Million Public Offering

October 9, 2024

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

October 3, 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

September 15, 2024

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

September 5, 2024

Immatics Announces Second Quarter 2024 Financial Results and Business Update

August 12, 2024

Immatics Appoints Alise Reicin to Board of Directors

July 30, 2024

Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024

July 17, 2024

Immatics Announces First Quarter 2024 Financial Results and Business Update

May 13, 2024

Immatics Announces Full Year 2023 Financial Results and Corporate Update

March 20, 2024

Immatics Announces Proposed Public Offering

January 16, 2024

Immatics Announces Pricing of $175 Million Public Offering

January 16, 2024

Decks in 2024